Non–Small Cell Lung Cancer Coverage from Every Angle
ABOUT
SECTIONS
JNCCN Spotlights
Videos
News
Medical Literature
CE Activities
Clinical Trials
For Your Patients
NCCN RESOURCES
NCCN Guidelines
®
NCCN Compendium
®
NCCN Templates
®
NCCN Guidelines for Patients®
360 HUB
Advanced Skin Cancers
CLL/MCL
Multiple Myeloma
Non–Small Cell Lung Cancer
Ovarian Cancer
JNCCN
Editor:
Gregory J. Riely, MD, PhD
Advertisement
Advertisement
News
ADAURA Update: Adjuvant Osimertinib Maintains Overall Survival Benefit at 8 Years in EGFR-Mutated NSCLC
Amivantamab and Chemotherapy Prolong OS in Previously Untreated EGFR ex20ins NSCLC
Early Trial Supports Phase III Evaluation of Daraxonrasib in RAS-Mutant NSCLC
FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous NSCLC
Does the Timing of Immunotherapy Administration Influence Survival Outcomes in Advanced Cancers?
Guideline-Concordant Lymph Node Sampling Does Not Increase Complications After NSCLC Resection
Zidesamtinib Approved for Second-Line Treatment of
ROS1
-Positive NSCLC
ASCO 2026: HARMONi-6 Meets Overall Survival Endpoint in Advanced Squamous NSCLC
ASCO 2026: Adjuvant Selpercatinib in Early-Stage
RET
Fusion–Positive NSCLC
AACR 2026: Zoldonrasib Shows Promising Responses in
KRAS
G12D–Mutated Lung Cancer
Predicting Overall Survival in Metastatic NSCLC: Daily Step Count vs ECOG Performance Status
JNCCN Spotlights
?
(UPDATE) Nivolumab in NSCLC
Dabrafenib + Trametinib
Repotrectinib for ROS1-Positive NSCLC
View More >
Advertisement
Resources
For your Patients
Copyright ©
2026
National Comprehensive Cancer Network, All Rights Reserved
Bots not welcome here
